Re-emergence of acute myeloid leukemia in donor cells following allogeneic transplantation in a family with a germline DDX41 mutation

Leukemia

Volumn 31, Issue 2, 2017, Pages 520-522

  Berger, G ^a   Van Den Berg, E ^a   Sikkema Raddatz, B ^a   Abbott, K M ^a   Sinke, R J ^a   Bungener, L B ^a   Mulder, A B ^a   Vellenga, E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; AZACITIDINE; DEAD BOX HELICASE 41; DEAD BOX PROTEIN; DNA METHYLTRANSFERASE 3A; UNCLASSIFIED DRUG; DDX41 PROTEIN, HUMAN;

ACUTE MYELOID LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ASXL1 GENE; CANCER CHEMOTHERAPY; CASE REPORT; CHIMERA; DONOR SELECTION; FAMILY HISTORY; GENE; GENE FREQUENCY; GENETIC VARIABILITY; GERMLINE MUTATION; HUMAN; KARYOTYPE; LETTER; MALE; MIDDLE AGED; MOLECULAR GENETICS; MYELODYSPLASTIC SYNDROME; PANCYTOPENIA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; SANGER SEQUENCING; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TRANSCRIPTION INITIATION SITE; WHOLE EXOME SEQUENCING; ALLOTRANSPLANTATION; DONOR; FAMILY; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA, MYELOID, ACUTE; PROCEDURES;

DEAD-BOX RNA HELICASES; FAMILY; GERM-LINE MUTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84995814861     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.310     Document Type: Letter

References (15)

1. Babushok DV, Bessler M, Olson TS. Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults. Leuk Lymphoma 2016; 57: 520-536.
2. Churpek JE, Pyrtel K, Kanchi KL, Shao J, Koboldt D, Miller CA et al. Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. Blood 2015; 126: 2484-2490.
3. Cardoso SR, Ryan G, Walne AJ, Ellison A, Lowe R, Tummala H et al. Germline heterozygous DDX41 variants in a subset of familial myelodysplasia and acute myeloid leukemia. Leukemia 2016; 30: 2083-2086.
4. Li R, Sobreira N, Witmer PD, Pratz KW, Braunstein EM. Two novel germline DDX41 mutations in a family with inherited myelodysplasia/acute myeloid leukemia. Haematologica 2016; 101: e228-e231.
5. Tawana K, Fitzgibbon J. Inherited DDX41 mutations: 11 genes and counting. Blood 2016; 127: 960-961.
6. Lewinsohn M, Brown AL, Weinel LM, Phung C, Rafidi G, Lee MK et al. Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignancies. Blood 2016; 127: 1017-1023.
7. Polprasert C, Schulze I, Sekeres MA, Makishima H, Przychodzen B, Hosono N et al. Inherited and somatic defects in DDX41 in myeloid neoplasms. Cancer Cell 2015; 27: 658-670.
8. Lowenberg B, Pabst T, Vellenga E, van PW, Schouten HC, Graux C et al. Cytarabine dose for acute myeloid leukemia. N Engl J Med 2011; 364: 1027-1036.
9. Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009; 41: 838-842.
10. Kalb R, Neveling K, Hoehn H, Schneider H, Linka Y, Batish SD et al. Hypomorphic mutations in the gene encoding a key Fanconi anemia protein, FANCD2, sustain a significant group of FA-D2 patients with severe phenotype. Am J Hum Genet 2007; 80: 895-910.
11. Thol F, Friesen I, Damm F, Yun H, Weissinger EM, Krauter J et al. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol 2011; 29: 2499-2506.
12. Metzeler KH, Herold T, Rothenberg-Thurley M, Amler S, Sauerland MC, Gorlich D et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood 2016; 128: 686-698.
13. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG et al. Agerelated clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014; 371: 2488-2498.
14. Woolthuis CM, Brouwers-Vos AZ, Huls G, de Wolf JT, Schuringa JJ, Vellenga E. Loss of quiescence and impaired function of CD34(+)/CD38(low) cells one year following autologous stem cell transplantation. Haematologica 2013; 98: 1964-1971.
15. Raaijmakers MH, Mukherjee S, Guo S, Zhang S, Kobayashi T, Schoonmaker JA et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 2010; 464: 852-857.